OncoCyte
Oncocyte Laying off 40 Percent of Staff, Selling DetermaRx Test
The company has entered into a stock purchase agreement to sell 70 percent of its stake in Razor Genomics and has eliminated its COO and CSO positions.
People in the News at Oncocyte, PrognomiQ, BillionToOne, Haystack Oncology, More
Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Nov. 28, 2022.
BTIG Downgrades Oncocyte to Neutral Following News of CEO Departure
In an announcement late Wednesday, the company said Ronnie Andrews had stepped down, marking the firm's third major executive to depart in recent months.
Earnings Roundup: HTG Molecular, T2 Biosystems, Co-Diagnostics, Biocept, Oncocyte, OpGen
The genomic and diagnostics firms posted quarterly financial results late this week.
SWOG to Use Oncocyte's DetermaIO Test in Cancer Biomarker Study
The DetermaIO test will be used to analyze triple negative breast cancer tissue as a secondary endpoint in the Phase III S1418 clinical trial.